Tano Pharmaceuticals Completes RMB 264 Million Series D Financing to Advance Late-Stage Clinical Trials of Lead Candidates

VCBeat (WeChat ID: vcbeat) has learned that TenNor Therapeutics (Suzhou) Co., Ltd. announced the completion of its RMB 264 million Series D financing round, co-led by Yanchuang Capital and GTJA Investment, with participation from Xinghe Capital, Beisen Capital, Guolian XinChuang, Zhongnuo Venture Capital, and Yuanhe Holdings. The funds raised will be used to advance late-stage clinical trials of its core products.

TenNor Therapeutics is a clinical-stage, global innovative drug development company. Its product pipeline is primarily focused on disease areas with significant unmet clinical needs related to bacterial infections and dysbiosis. Currently, multiple indications for three of its core products have completed Phase II clinical trials and have entered international multicenter Phase III clinical trials. The target indications for these products include infections associated with implanted medical devices, Helicobacter pylori infection, hepatic encephalopathy in liver cirrhosis, and diarrhea-predominant irritable bowel syndrome (IBS-D). To address the unmet clinical needs in these fields, TenNor Therapeutics holds global intellectual property rights for these products.

“This financing round will help TenNor Therapeutics advance its key products into Phase III clinical trials. We are delighted to have completed this round in the current investment climate, and we sincerely appreciate the recognition and support from our investors,” said Dr. Ma Zhenkun, Founder and CEO of TenNor Therapeutics. “We will continue to adhere to our need-oriented, science-driven approach to novel drug development, rapidly advancing our pipeline to bring valuable new therapies to patients as soon as possible.”

Ms. Liu Zeng, President of Yanchuang Capital, stated, “We are delighted to have the opportunity to participate in TenNor Therapeutics’ Series D financing. TenNor Therapeutics boasts an international new drug R&D team and, after years of dedicated efforts, has established a differentiated product portfolio in the fields of bacterial infections and microbiota dysbiosis-related diseases. Several of its products have entered pivotal Phase III clinical trials. We look forward to further collaboration with the TenNor Therapeutics team to help advance its product pipeline and strive to bring valuable therapeutic solutions to patients as soon as possible.”

Mr. Yu Jianlin, Executive Partner at GTJA Investment, stated: “TenNor Therapeutics is a leading enterprise in the field of bacterial infections and diseases associated with dysbiosis. We are highly optimistic about TenNor’s unique product R&D pipeline and its substantial future market potential. We are delighted to participate in this financing round, supporting TenNor in advancing its key products into Phase III clinical trials, while also leveraging GTJA’s industry resources in healthcare and wellness to continuously assist the company’s development. We look forward to and firmly believe that TenNor Therapeutics will become a globally leading innovator in anti-infective new drug development, enabling patients to benefit sooner.”

TenNor Therapeutics (Suzhou) Co., Ltd. is a clinical needs-driven company specializing in the development of differentiated novel drugs. It possesses a unique multi-target conjugate molecule drug discovery platform and a pipeline of novel drug candidates protected by global intellectual property rights. Currently, multiple products have entered late-stage clinical trials, with target indications including medical device-related biofilm infections, Helicobacter pylori infection, hepatic encephalopathy associated with liver cirrhosis, and diarrhea-predominant irritable bowel syndrome (IBS-D). The company is committed to addressing unmet clinical needs in these areas and providing safe and effective treatment solutions for patients in China and worldwide.

Founded in Shenzhen in 2001, GTJA Investment focuses on investments in the healthcare sector, with strategic equity investment as its core approach, covering all stages including mergers and acquisitions, private equity (PE), venture capital (VC), and angel investing. With a leading professional healthcare investment team in China, it has established an ecosystem platform for healthcare industry investment and is committed to becoming a globally influential healthcare investment institution. Currently, its assets under management exceed RMB 23 billion, with 25 healthcare-focused funds. It has invested in more than 160 companies (including over 90 in the healthcare sector) and facilitated the successful listing of 32 portfolio companies.

Yanchuang Capital, fully known as “Yanyuan Innovation Capital Group,” was founded in June 2010. Previously named “Yanyuan Capital Group,” it is an investment and capital operation platform for high-tech enterprises, jointly established by Peking University alumni engaged in venture capital and the commercialization of university technological achievements, under the advocacy and support of the Science and Technology Development Department of Peking University. Adhering to value investment as its core principle and upholding the corporate philosophy of “integrity, customer-centricity, professionalism, and excellence,” Yanchuang Capital began its strategic layout in the big health sector, including biopharmaceuticals, in 2018. To date, it has invested in dozens of globally leading and China’s top-tier biopharmaceutical and medical device companies. Yanchuang Capital will continue to expand its presence in the healthcare industry, dedicated to researching and investing in China’s first-class and world-leading innovative drug developers, high-end medical device manufacturers, CROs, and CDMOs, thereby making greater contributions to the development of China’s biopharmaceutical industry.